Vion (formerly Oncorx) interesting play on Gene Therapy Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jim Oravetz who wrote (164)	11/3/1999 12:37:00 PM
From: Jim Oravetz	Read Replies (1) of 370

NEW HAVEN, Conn. (Dow Jones)--Vion Pharmaceuticals Inc. (VION) completed the sale of an additional 330,00 common shares pursuant to an underwriter's overallotment option. The overallotment is related to Vion's offering of 2.2 million shares at $5 a share, which was completed on Oct. 29. In a press release Wednesday, the biopharmaceutical company said it received proceeds of about $1.53 million on the transaction. The combined proceeds from both transactions total about $11.15 million. Vion plans to use the proceeds for working capital, including product research and development, and other general corporate purposes. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next